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T cells engineered to express chimeric antigen receptors (CARs) against B cell antigens
are being investigated as cellular immunotherapies. Similar approaches designed to target
T cell malignancies have been hampered by the critical issue of T-on-T cytotoxicity,
whereby fratricide or self-destruction of healthy T cells prohibits cell product manufacture.
To date, there have been no reports of T cells engineered to target the definitive T cell
marker, CD3 (3CAR). Recent improvements in gene editing now provide access to efficient
disruption of such molecules on T cells, and this has provided a route to generation of
3CAR, CD3-specific CAR T cells. T cells were transduced with a lentiviral vector
incorporating an anti-CD3e CAR derived from OKT3, either before or after TALEN-mediated
disruption of the endogenous TCRab/CD3 complex. Only transduction after disrupting
assembly of TCRab/CD3 yielded viable 3CAR T cells, and these cultures were found to
undergo self-enrichment for 3CAR+TCR–CD3– T cells without any further processing.
Specific cytotoxicity against CD3e was demonstrated against primary T cells and against
childhood T cell acute lymphoblastic leukemia (T-ALL). 3CAR T cells mediated potent
antileukemic effects in a human/murine chimeric model, supporting the application of
cellular immunotherapy strategies against T cell malignancies. 3CAR provides a bridging
strategy to achieve T cell eradication and leukemic remission ahead of conditioned
allogeneic stem cell transplantation.
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Introduction
T cell acute lymphoblastic leukemias (T-ALL) and T cell lymphoblastic lymphoma account for around 15% 
of pediatric and 25% of adult ALL. These are heterogeneous conditions and often exhibit extramedullary and 
CNS involvement. Outcome for childhood T-ALL has improved over time with advances in pediatric ALL 
therapy, and long-term survival is over 75% (1). Nonetheless, most relapsing subjects face high levels of  mor-
bidity and mortality, and survival in adults is less favorable, highlighting a need for innovative interventions.
There has been notable progress in the development of  engineered T cell therapies against B cell malig-
nancies, and chimeric antigen receptors (CARs) against B cell antigens including CD19, CD20, CD22, and 
other targets have proven highly effective against refractory B cell leukemia (2). CARs usually comprise an 
extracellular domain derived from an antibody single-chain variable fragment (scFv), linker, transmem-
brane moiety, and activation domains derived from combinations of  CD28, 41BB, and CD3 (3). Most of  
these therapies have been generated in a bespoke manner using autologous or HLA-matched allogene-
ic peripheral blood mononuclear cell (PBMC) harvests, although recently nonmatched universal donor 
CAR19 T cells manufactured using TALEN (transcription activator-like effector nuclease) gene editing 
have been reported (4, 5). The development of  similar approaches against T cell malignancies has been 
extremely challenging, not least because of  fratricidal T-on-T cytotoxicity during cell manufacture. Certain 
cell surface antigens such as CD5 (6) have been targeted using specific CARs, and downregulation of  their 
expression in activated T cells has allowed effector cells to expand and yield a product. Similarly, CD4 has 
been targeted by CD8+ T cells expressing a CD4-specific CAR (7), and CARs discriminating between T 
cell receptor constant regions (TRBC1 or TRBC2) have also been developed, with the aim of  eradicating 
whichever of  the 2 compartments malignant transformation may have arisen in (8). In addition, CRIS-
PR/Cas9-mediated disruption of  CD7 expression has also recently been reported in T cells transduced 
to express a CD7-specific CAR (9), as well as alternative strategies deploying an anti-CD7 scFv linked to 
T cells engineered to express chimeric antigen receptors (CARs) against B cell antigens are 
being investigated as cellular immunotherapies. Similar approaches designed to target T cell 
malignancies have been hampered by the critical issue of T-on-T cytotoxicity, whereby fratricide 
or self-destruction of healthy T cells prohibits cell product manufacture. To date, there have 
been no reports of T cells engineered to target the definitive T cell marker, CD3 (3CAR). Recent 
improvements in gene editing now provide access to efficient disruption of such molecules on T 
cells, and this has provided a route to generation of 3CAR, CD3-specific CAR T cells. T cells were 
transduced with a lentiviral vector incorporating an anti-CD3ε CAR derived from OKT3, either before 
or after TALEN-mediated disruption of the endogenous TCRαβ/CD3 complex. Only transduction 
after disrupting assembly of TCRαβ/CD3 yielded viable 3CAR T cells, and these cultures were found 
to undergo self-enrichment for 3CAR+TCR–CD3– T cells without any further processing. Specific 
cytotoxicity against CD3ε was demonstrated against primary T cells and against childhood T cell 
acute lymphoblastic leukemia (T-ALL). 3CAR T cells mediated potent antileukemic effects in a 
human/murine chimeric model, supporting the application of cellular immunotherapy strategies 
against T cell malignancies. 3CAR provides a bridging strategy to achieve T cell eradication and 
leukemic remission ahead of conditioned allogeneic stem cell transplantation.
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endoplasmic reticulum retention domains, to prevent cell-surface expression of  CD7 (10). Furthermore, 
CD7 specific universal CAR T cells depleted  of  both CD7 and T cell receptor expression have also been 
generated (11). However, to date, there have been no reports to our knowledge of  CAR T cell strategies tar-
geting the definitive T cell marker CD3. Previous attempts to generate anti-CD3 CAR cells have been limit-
ed to NK cells that did not express CD3 but were then able to specifically eliminate CD3+ lymphoma lines 
and primary T cell targets in vitro, as well as CD3+ Jurkat leukemic T cells in human/murine chimeras (12).
We report anti–T cell immunotherapy using 3CAR, a CAR against the CD3ε chain of  the T cell 
receptor complex, generated by fusing the scFv regions of  OKT3, a widely used anti-CD3ε monoclonal 
antibody, with a transmembrane stalk and intracellular activation domains from 41BB and CD3ζ (Figure 
1A). Effective manufacturing of  anti-CD3–specific T cells was only possible following critically scheduled 
TALEN-mediated disruption of  the TCRαβ/CD3 complex; once modified, 3CAR T cells rapidly domi-
nated cultures and self-enriched without the need for further processing to deplete residual TCRαβ T cells 
required for other gene-edited CAR T cells (5). Anti-CD3 cellular immunotherapy could deliver valuable 
antileukemic effects in relapsed refractory disease and, in the first instance, would be deployed as a form of  
cellular conditioning to secure molecular remission ahead of  allogeneic stem cell transplantation.
Results
We generated 3CAR by fusing the scFv fragment of  OKT3 (a therapeutic-use anti-CD3ε monoclonal anti-
body) to a CD8 transmembrane region linked to 41BB and CD3ζ signaling domains. Lentiviral expression 
of  3CAR (Figure 1A) in cell lines lacking expression of  CD3ε (HEK293T cells) was found to be stable, dose 
dependent, and saturable at high multiplicities of  infection (MOI) (Supplemental Figure 1A; supplemen-
tal material available online with this article; https://doi.org/10.1172/jci.insight.99442DS1). However, in 
primary CD3+ T cells, lentiviral transduction of  T cells activated with anti-CD3/CD28 (TransAct reagent) 
resulted in inefficient 3CAR gene transfer, with only around 10% modified cells present after 4 days and 
none detectable by day 11 (Supplemental Figure 1B) as a result of  T-on-T cytotoxicity. In order to alleviate 
3CAR-mediated destruction of  T cells, gene editing was employed to disrupt assembly of  the multimeric 
TCRαβ/CD3 complex. We reasoned that disruption and nonhomolgous end joining–mediated repair of  the 
T cell receptor α constant (TRAC) locus would not only prevent expression of  TCRα, but also disrupt cell-sur-
face CD3ε expression. First, we attempted to dissemble the TCRαβ/CD3 multimeric complex expression 
on T cells by electroporation of  TRAC-specific TALEN mRNA immediately after activation and lentiviral 
transduction with 3CAR (Supplemental Figure 1C). This reflected our existing approach for the generation 
of  universal TCRαβ–CAR19+ T cells (4, 5). This order of  transduction followed by editing was known to sup-
port high levels of  proliferation in T cells, and it was hypothesized that constitutive CAR signaling in TCR– T 
cells provides resilience and promotes survival through subsequent gene-editing steps. Whilst around 80% 
of  cells were disrupted for both CD3 and TCRαβ, the eventual 3CAR T cell yield was poor (Figure 1B and 
Supplemental Figure 1, C and D), in contrast to CAR19 vectors, and this suggested widespread targeting of  
CD3ε antigen leading to self  destruction and/or rapid fratricide of  other CD3+ T cells in the culture.
Next, the event sequence was reversed to first deplete endogenous CD3ε expression in activated T cells, 
and then undertake lentiviral (LV) transduction within an 18- to 24-hour time window (Figure 1, C and D, 
and Supplemental Figure 2). Here, within 7 days of  initiation, 57% of  T cells expressed 3CAR (Figure 1E) 
with approximately equal proportions of  CD4+ and CD8+ T cells (Figure 1F) and with comparable out-
comes to vectors expressing CAR19 (Figure 1, G and H). Importantly, the cultures self-enriched for T cells 
devoid of  CD3/TCRαβ, obviating the need for any further processing to deplete residual TCR+ T cells that 
comprised <0.2% of  the product. In contrast, residual TCR+ populations in TCR–CAR19+ cell products 
required removal by bead-mediated depletion by targeting TCRαβ to achieve a target of  <1%TCR+ cells in 
the final product. This is a stringent threshold that strongly influences allogeneic dosing strategies where 
graft versus host disease (GVHD) is considered unlikely by capping TCRαβ carriage to <5 × 104/kg.
To assess scalability, cells were activated, edited, and transduced, and 2 × 106 3CAR T cells were 
cultured further in a gas-permeable static cell culture flask (G-Rex). Cells expanded by 100-fold over 11 
days (Figure 2A) and were devoid of  TCR/CD3-expressing cells with residual populations of  <0.5% (Fig-
ure 2B). After electroporation of  TRAC TALEN mRNA, CD3+TCR+ T cells were selectively depleted in 
3CAR T cell cultures (Figure 2B). Tracking indels by decomposition PCR(TIDE PCR) sequencing across 
the TRAC locus confirmed an allele-modification frequency of  62.9% based on molecular signatures of  
nonhomologous end joining repair (Figure 2C). As the TRAC locus exhibits allelic exclusion (13), this fre-
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Figure 1. Successful generation of 3CAR requires disruption of CD3ε expression prior to lentiviral 3CAR transduction. (A) Vector configuration 
showing codon optimized single-chain variable fragment (scFv) derived from OKT3 with CD8 stalk and 41BB/CD3ζ activation domains, all under the 
control of an internal human phosphoglycerate kinase (hPGK) promoter in a third-generation self-inactivating (SIN) lentivirus with HIV-1–derived 
reverse response element (RRE), central polypurine tract (cPPT), and mutated woodchuck hepatitis virus posttranscriptional regulatory element 
(WPRE). Human cytomegalovirus (CMV); Repeat region (R); Unique 5’ region (U5); Psi (Ψ); and modified unique 3’ region (ΔU3). (B) Percentage of 
CAR+ cells with and without TRAC-KO prior to lentivirus (LV). Data are presented as mean ± SEM. n = 3 donors. (C) Schema of event precedence 
required for successful 3CAR T cell production. CD3/CD28 activation with TransAct for 48 hours was followed by electroporation of mRNA encod-
ing TRAC-specific TALENs ahead of LV transduction by 72 hours. (D) Summary of CD3+ cells following TRAC-KO (n = 3 donors), mean ± SEM. ***P < 
0.0005, by unpaired, 2-tailed Student’s t test. (E) Representative flow cytometry plots of day 7 cells. In cultures with 3CAR expression, there were no 
surviving CD3+ cells compared with 20% residual expression in the absence of 3CAR transduction (n = 3 donors). (F) Representative flow cytometry 
plots showing 3CAR T cells retained CD4 and CD8, but not TCRαβ, expression; n = 3 donors. (G) For comparison, control transductions with LV CAR19 
mediated 65% transduction but required further processing by column-mediated TCRαβ depletion to yield TRAC-KO CAR19+ T cells; n = 3 donors. (H) 
Summary of CAR+ cells following TRAC-KO (n = 3 donors); mean ± SEM. Two-tailed Student’s t test.
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quency of  modification was consistent with the near-complete TCR disruption assessed by flow analysis. 
Flow cytometric analysis for relevant subset markers was performed at the end of  expansion (gated on 
CAR+ and CAR– populations) and revealed enrichment of  3CAR T cells (CD4+ and CD8+) and negligible 
residual B cells (CD20) or NK cells (CD56). There was very little change in expression of  T cell exhaus-
tion markers PD-1, LAG-3, and TIM-3 (Figure 2D), and the majority of  3CAR T cells exhibited a central 
memory phenotype (Tcm CD45–CD62L+) or stem cell memory phenotype (stem memory T cell [Tscm] 
CD45+CD62L+CD95+) (Figure 2E and Supplemental Figure 3). 3CAR T cells exhibited IFN-γ production 
responses against TCR/CD3+ Jurkat leukemia cells (Supplemental Figure 4) and mediated CD3ε-specific 
cytotoxicity in vitro. Chromium 51–labeled (51Cr-labeled) TCR/CD3+ or TCR/CD3– Jurkat leukemia cells 
(14) were cocultured with either 3CAR T cells or nontransduced control T cells. 3CAR+ T cells mediated 
specific high-level cytotoxicity of  targets expressing TCR/CD3+ but not TCR/CD3– targets (Figure 3, A 
and B). Next, a flow-based assay also confirmed that EGFP+TCR/CD3+ Jurkat cells were almost complete-
ly eliminated by 3CAR cells (0.8%), compared with untransduced effector controls (61%). TCR/CD3– leu-
kemia cells were unaffected by 3CAR (57%) or effector controls (54%) (Figure 3, C and D). 3CAR T cells 
also mediated cytotoxic effects against purified primary CD3+ T cells is loaded with carboxyfluorescein 
succinimidyl ester (CFSE) dye. Only around 4% of  these cells survived, compared with 42% in control 
cultures, and TCR/CD3– purified populations were not eliminated by 3CAR cells, confirming specificity 
against CD3ε (Figure 3, C and D).
To further evaluate the function of  3CAR T cells, cultures were established against allogenic and autol-
ogous primary healthy donor PBMC. 51Cr-labeled allogenic or autologous PBMC were cocultured with 
either 3CAR T cells or nontransduced control T cells. In both settings, 3CAR+ cells mediated high-level 
cytotoxicity compared with untransduced effector cells (Figure 4A). On a single-cell level, flow cytometry 
analysis confirmed the high level of  specific cytotoxicity mediated by 3CAR cells. CFSE-loaded healthy 
donor PBMC cultured with 3CAR T cells resulted in reduced CD3-expressing cells (8% CD3+ cells) com-
pared with untransduced T cell effectors (93% CD3+ cells), without eliminating CD7+CD3– cells, nor 
CD19+ B cells, whereas control CAR19 cells did not target T-lymphocytes (Figure 4B). 3CAR T cells 
cultured with allogeneic PBMC or purified allogeneic TCR/CD3+ T cells exhibited IFN-γ responses and 
low-level secretion of  TNF-α, IL-10, IL-6, and IL-4 (Figure 4C and Supplemental Figure 4). 3CAR T 
cells also exhibited notable 3H-thymidine proliferation responses when cocultured with irradiated allogenic 
CD3+ T cells. Proliferation against irradiated allogeneic CD3-depleted PBMC was reduced, but control T 
cell–mediated allorecognition was intact (Figure 4D). These data suggest that 3CAR can mediate elimina-
tion of  healthy TCRαβ/CD3 T cells, an effect that could be harnessed during lymphodepletion procedures 
ahead of  allogeneic transplantation.
The function of  3CAR T cells was also assessed against viable tissue bank samples from children with 
T-ALL. Flow cytometry verified CD3, CD7, CD19, and CD34 expression upon thawing in these targets 
(Table 1). In the case of  T-ALL#1 cells, 86% CD3-expressing cells were almost completed eliminated by 
3CAR+ cells (Figure 5A). Despite the phenotypic heterogeneity of  the T-ALL, in 6 of  6 samples, 3CAR 
cells displayed highly specific cytotoxicity against CD3+ but not CD3–CD19+ cells, CD3–CD7+ cells, and 
CD3–CD34– cells (Figure 5, B and C, and Supplemental Figure 5).
In vivo functionality of  3CAR T cells was assessed in a humanized murine model of  leukemic 
T cell clearance. NOD/SCID/γc–/– (NSG) mice were inoculated i.v. with 10 × 106 TCR/CD3+EGF-
P+LUC+ or TCR/CD3–EGFP+LUC+ Jurkat T cell targets and imaged after 3 days to confirm leuke-
mia establishment, and they were then injected with effector cells. These comprised either 3CAR or 
untransduced effector T cells. Serial bioluminescence imaging on days 3–18 showed rapid clearance of  
TCR/CD3+ Jurkat cells in the cohort receiving 3CAR T cells, with negligible signal detected by day 
11, in contrast to mice receiving nontransduced T cells or PBS where leukemia progressed (Figure 6, A 
and B). By day 18, disease burden had increased by >60-fold in animals receiving untransduced effec-
tors compared with the 3CAR effector group (Figure 6C). As expected, neither 3CAR effectors nor 
control T cells exhibited an antileukemic effect against TCR/CD3– Jurkat cells lacking target antigen 
expression (Supplemental Figure 6). At necroscopy, flow cytometry was used to detect EGFP+ Jurkat 
T cells and/or CD45+CD2+EGFP– effector T cell populations in BM (Figure 6D). Analysis from day 
18 samples found complete clearance of  TCR/CD3+ Jurkat T cells in 5 of  5 animals in 3CAR-treated 
animals compared with control animals receiving PBS or untransduced T cells (Figure 6D and Supple-
mental Figure 6A). In most animals, only very small numbers of  TCR–EGFP+ Jurkat cells were iden-
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Figure 2. 3CAR T cell expansion and self-enrichment. (A) Primary T cells were activated, and following TALEN TRAC mRNA exposure, 2 × 106 T cells 
were transduced and expanded in a G-Rex flask over 17 days; n = 2 donors. (B) Representative expression of CD3/TCR in TRAC-KO untransduced (top 
panel) and 3CAR T cells (lower panel) on day 7 and 13, confirming the absence of CD3/TCRαβ cells after 3CAR lentiviral expression; n = 3 donors. (C) 
Tracking indels by decomposition PCR (TIDE-PCR) confirmed 62.9% of alleles harbored molecular signatures of nonhomologous end joining across 
the TRAC locus (n = 2). (D) Representative flow cytometry plots at end of manufacture for CD20 and CD56 expression and exhaustion markers PD-1, 
LAG-3, and TIM-3 (gated on CAR+ and CAR– populations); n = 3 donors. (E) The percentage of memory T cell markers on expanded day 17 cells; n = 3 
donors, mean ± SEM.
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tified, except 1 animal where there appeared to have been an outgrowth of  CD3–EGFP+ Jurkat cells 
that had presumably not been to susceptible to 3CAR-mediated killing (Figure 6E and Supplemental 
Figure 7). 3CAR effectors retained expression of  their chimeric receptor and CD4+/CD4– marking at 
levels comparable with those in the original inoculum (Figure 6D and Supplemental Figures 7 and 8). 
Although 3CAR expression (24%) was detected in animals engrafted with CD3–TCR– Jurkat cells, the 
absence of  suitable target antigen resulted in rapid accumulation of  disease in these animals (Supple-
mental Figure 7).
Figure 3. 3CAR T cells 
mediate potent killing 
of CD3+ cells in vitro. (A) 
TCR+ and TCR– Jurkat target 
cells were stained for TCR 
expression prior to coculture 
experiments. (B) 51Cr-labeled 
CD3+TCR+ (white symbols) 
or CD3–TCR– (black symbols) 
Jurkat leukemia cells were 
cocultured with either 3CAR T 
cells (solid lines) or untrans-
duced controls (dotted lines); 
(n = 3) from 3 donors. (C) 
Upper panel, 3CAR T cells 
were cocultured with either 
GFP+CD3+TCR+ or GPP+CD3–
TCR– Jurkat leukemia cells 
and, in the lower panel, cocul-
tured with either CFSE-load-
ed primary CD3+ or CD3– cells 
at the effector target ratio 
of 1:1 for 24 hours. Represen-
tative flow cytometry plots 
of gated on GFP+ or CFSE+ 
cells at the end of coculture 
demonstrate target-specific 
killing. (D) Summary of 3CAR 
cytotoxicity as in C where 
data are presented as mean ± 
SEM; n = 3 per group. ***P < 
0.0005, by unpaired, 2-tailed 
Student’s t test.
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Discussion
Following successful elimination of  B cell malignancies using CAR T cells targeting a variety of  B cell 
antigens (most notably CD19), attempts are underway to generate similar therapies against T cell malig-
nancies. Recent publications have reported targeting CD5 and CD7, the latter in combination with CRIS-
Figure 4. 3CAR T cell functionality against healthy donor PBMC. (A) 51Cr-labeled peripheral blood mononuclear cell (PBMC) in autologous (dotted lines) or 
allogenic (solid lines) coculture. PBMC were cultured with either 3CAR T cells (white symbols) or untransduced controls (black symbols) (n = 3). (B) 3CAR, 
CAR19, or untransduced T cells were cocultured with CSFE-loaded healthy donor PBMC at the effector target ratio of 1:1 for 24 hours. Top panel shows 
representative frequency of gated CSFE+ target cells at the end of coculture. Flow cytometry plots below show representative frequency of surface antigen 
markers CD3, CD19, and CD7 on gated CSFE+ tumor cells, displaying the specificity in mixed cell populations; n = 3 donors. (C) Cytokine production by 3CAR 
T cells when cocultured with healthy donor PBMC target cells were comparable with untransduced cells; n = 3 donors. (D) Mixed lymphocyte reactions of 
3CAR or untransduced T cells cultured with irradiated (*) allogeneic PBMC or CD3– cells. 3H-thymidine proliferation responses are consistent with specific 
targeting of CD3 rather than alloreactive proliferation); mean ± SEM, 4 experimental replicates (n = 2 donors). #P < 0.05, by unpaired, 2-tailed Student’s t 
test. Corrected counters per minute, CCPM.
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PR-mediated disruption of  endogenous CD7 expression on T cells. To date, there have been no reports to 
our knowledge of  CAR therapy targeting the definitive T cell marker CD3, which is widely expressed on 
T cell lymphomas and also expressed with variable levels of  intensity on acute T cell leukemias. Previous 
attempts to generate anti-CD3 CAR cells have only been successful using NK cells that did not express 
CD3. CD3CAR NK-92 cells were shown to specifically eliminate CD3+ lymphoma cell lines and primary 
T cell targets in vitro and CD3+ Jurkat cells in human/murine chimeras (12).
The gene-editing platform used in this iteration of  3CAR was based on TALENs and extends our previ-
ous experience with similar reagents for CAR19 aimed at securing molecular remission ahead of  allo–stem 
cell transplantation (allo-SCT) for relapsed/refractory B-ALL. We reported minimal evidence of  off-target 
effects using high-throughput NGS interrogation of  in silico predicted activity of  TRAC-specifc TALENs 
(5). Alternative editing platforms may be as effective, although are likely to need to operate within a similarly 
well-defined window of activity to ensure target antigen removal before 3CAR expression.
We have found that gene editing to disrupt TCR expression can be exploited to enable 3CAR T cells 
to be generated through avoidance of  T-on-T killing and fratricide effects. Previously described TALENs 
specific for the TRAC locus (15) were delivered by electroporation of  mRNA and mediated highly efficient 
disruption of  the TCRα chain, which in turn resulted in failure to assemble cell-surface CD3/TCR com-
plexes. A therapeutic monoclonal antibody OKT3 targeting CD3ε has been previously used in transplant 
settings to lymphodeplete T cells. The scFv of  this antibody was incorporated into a CAR configuration by 
fusion to a CD8 transmembrane region, 41BB signaling domain, and CD3ζ elements. Delivery by lentiviral 
vector was combined with delivery of  TALEN mRNA and conditions investigated to determine optimal 
order of  events for effective production of  TCR–3CAR+ T cells. In previous campaigns, we had found that 
the generation of  universal TCR–CAR19+ T cells was most efficient when TRAC disruption was performed 
after lentiviral transduction. However, a similar schedule for 3CAR resulted in poor yields, presumably 
because prior expression of  3CAR mediated detection of  CD3ε. A strictly ordered sequence of  TRAC dis-
ruption ahead of  3CAR expression was found to be essential for the generation of  3CAR, and this event 
precedence was incorporated into scaled production of  effector cells.
This strictly ordered sequence of  TRAC disruption ahead of  3CAR expression was incorporated into 
scaled production of  effector cells. The resulting 3CAR cells were characterized in detail by flow cytome-
try, cytokine profiles, and functional assessments of  alloreactivity and cytotoxicity. The potency of  these 
responses was also confirmed in a human/murine chimeric model where animals infused with 3CAR had 
greatly reduced tumor burdens compared with control groups.
The expression of  CD3 on leukemic T cells can be variable, but critically 3CAR-mediated cytotoxicity 
of  CD3+ targets was near complete in 6 of  6 samples evaluated. It is likely that, for effective elimination 
of  heterogenous leukemias, a strategy targeting multiple T cell antigens will be required, akin to combi-
national antibiotic therapy for mycobacterial disease or antiviral therapy against HIV. Based on our anal-
ysis, a combination of  CARs targeting CD3 and CD7 could be highly effective against childhood T-ALL. 
Applications in patients with CD3+ ALL refractory to conventional chemotherapy is envisaged, most likely 
as a bridge to transplant after achieving molecular remission. There are trials ongoing whereby universal 
CART19 (https://clinicaltrials.gov/; NCT02808442) for B-ALL or UCART123 (NCT03190278) or AML 
are being tested for their ability to secure remission ahead of  allo-SCT. Similarly, premanufactured 3CAR 
Table 1. Immunophenotype of 6 T-ALL samples tested
Percent expression of surface 
antigen (± 2%) 
CD3 CD7 CD19 CD34
T-ALL#1 86 83 11 1.5
T-ALL#2 40 86 10 8
T-ALL#3 43 94 0 33
T-ALL#4 21 98 0 94
T-ALL#5 7 96 16 38
T-ALL#6 1.5 94 0.5 96
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T cells from a non-HLA–matched allogeneic donor could be used in an off-the-shelf  manner for refracto-
ry T cell malignancy. However, elimination of  effector cells will be critical because, whereas suppression 
of  the normal B cell compartment by persisting CAR19+ T cells can be addressed by administration of  
replacement immunoglobulin therapy, long-term T cell lymphopenia mediated by 3CAR would be pro-
hibitive. Inclusion of  a suicide gene mechanism could be used for elimination of  3CAR cells, and we have 
confirmed the feasibility of  incorporating such elements in our lentiviral system. Alternatively, additional 
conditioning and/or serotherapy could be used to eradicate 3CAR, ahead of  donor-derived T cell recon-
stitution in the allogeneic stem cell transplantation setting, and this has been achieved using combinations 
of  serotherapy and chemotherapy. Highly effective, high-depth 3CAR cell–based eradication of  host T cell 
immunity may also be of  broader interest as a transplant conditioning strategy as an alternative to intensive 
chemotherapy–based lymphodepletion.
Methods
Cell lines. TCR/CD3+ and TCR/CD3– Jurkat cells (acute T cell leukemic cell line from ATCC) were main-
tained in culture in RPMI-1640 (Thermo Fisher Scientific) supplemented with10% FBS (MilliporeSigma).
Generation of  anti-CD3 CAR. 3CAR was derived by codon optimization (GeneArt) of  variable heavy-
chain and variable light-chain antigen binding elements of  the mouse anti–human CD3 monoclonal anti-
body, OKT3 sequence (16).The scFv was linked to activation domains derived from 41BB and CD3ζ. The 
resultant 3CAR construct was cloned into a lentiviral vector (pCCL) under the control of  a PGK promoter 
(Figure 1). Vector stocks pseudotyped with a vesicular stomatitis virus glycoprotein (VSV-G) envelope were 
generated in 293T cells (ATCC) and yielded titres >1 × 109 transducing units/ml after ultracentrifugation 
(17) and included control LV-CAR19 vectors (18).
Generation of  CAR-modified T cells. PBMC were obtained from healthy donors and were cultured in 
48-well plates at a density of  1 × 106/ml in TexMACS (Miltenyi Biotec), 3% human serum (Seralab) + 
Figure 5. 3CAR T cells specifically target CD3 in childhood T-ALL 
patient cells. (A) Representative flow cytometry plots gated on 
CSFE+ T-ALL tumor cells. Lower panel shows representative frequen-
cy of surface antigen CD3 and CD19 of gated CSFE+ tumor cells. (B) 
Percentage of CD3+ (n = 6) or CD19+ (n = 4) cells as in A from T-ALL 
donors. *P < 0.05, by unpaired, 2-tailed Student’s t test. (C) 3CAR 
(lower panels) or untransduced T cells (upper panels) were cocul-
tured with CSFE-loaded T-ALL patient donors at the effector target 
ratio of 1:1 for 24 hours. Flow cytometry plots show the frequency 
of CD3 and CD34 cells gated on CSFE+ T-ALL tumor cells. Four of 6 
patient samples were positive for CD34 expression.
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Figure 6. Antileukemic responses by 3CAR effector T cells against CD3+TCR+ GFP/luciferase human leukemia in immunodeficient mice. (A) Serial 
bioluminescence imaging (BLI) of NSG mice (representative images from each cohort) following i.p. administration of D-luciferin substrate showing 
elimination of CD3+ leukemia by 3CAR T cells but not by untransduced T cells. (B) Kinetics of systemic leukemia progression in mice following admin-
istration PBS (n = 2), untransduced T cells (n = 4), or 3CAR (n = 5) effectors. Error bars represent median with interquartile range. Linear regression 
analysis showed significance between 3CAR vs. untransduced (****P < 0.0001) and 3CAR vs. PBS (****P < 0.0001) groups. (C) Average radiance val-
ues at termination (day 18) indicated significant difference in disease burden between untransduced and 3CAR effector–injected groups (*P = 0.0159 
by Mann-Whitney U test). Error bars represent median with interquartile range. (D) Upper panel, representative flow cytometry plots of T cells (gated 
on hCD45+ cells) in BM. Middle panel, plots of leukemic T cell (CD3+TCR+GFP+ Jurkat targets) after effector challenge (gated on hCD45+CD2+ cells). 
Lower panel, plots of CAR T cells population (gated on hCD45+CD2+GFP– expression). (E) Proportion of GFP+ Jurkat leukemia or GFP– effector T cells 
out of CD45+CD2+ population in BM of untransduced or 3CAR-injected mice. Red marking highlights an animal that exhibited selective outgrowth of 
GFP+CD3– Jurkat cells after 3CAR therapy.
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20 ng/ml human recombinant IL-2 (Miltenyi Biotec), and activated with TransAct reagent (Miltenyi 
Biotec). Activated T cells were electroporated with TALEN_TCR_2a Right and Left mRNA (TRAC 
TALEN mRNA) (15) (TriLink Biotechnologies). On day 2, cells were divided into untransduced controls 
or transduced with CD3-CAR vector at a MOI of  5.
Flow cytometry. Cells were stained with the following primary anti-human antibodies: mouse anti–
human CD2 (clone LT2), mouse anti–human CD3 (clone BW264/56), mouse anti–human TCRαβ (clone 
BW242/412), mouse anti–human CD4 (clone VIT4), mouse anti–human CD8 (clone BW135/80), mouse 
anti–human CD19 (clone LT19), mouse anti–human CD20 (clone LT20), mouse anti–human CD56 (clone 
AF12-7H3), mouse anti–human CD279 (PD-1; clone PD1.3.1.3), mouse anti–human CD62L (clone 
145/15), and mouse anti–human CD45RA (clone T6D11) (all from Miltenyi Biotec); mouse anti–human 
TIM-3 (clone 7D3) and mouse anti–human LAG-3 (clone T47-530) (both from BD Pharmingen); mouse 
anti–human CD95 (clone DX2; BioLegend); and rat anti–mouse CD11b (clone M1/70; eBioscience).
To assess the efficiency of  CD3-CAR transduction, cells were stained using a Biotin-SP (long spacer) 
AffiniPure Fab Fragment Goat Anti-Mouse IgG fragment-specific antibody (catalog 115-066-072; Jackson 
Immunoresearch, Stratech Scientific Limited) followed by Streptavidin-APC (catalog 405207, BioLegend) 
or Streptavidin-FITC (catalog 405202, BioLegend). Cells were acquired on a Cyan or on a BD LSRII (BD 
Biosciences), and analysis was performed using FlowJo v10 (TreeStar Inc.).
Chromium release assay of  cytotoxicity. Cytotoxic activity of  3CAR cells was assessed by 51Cr release 
assay. For this, 5 × 103 51Cr-labeled TCR/CD3+ Jurkat cells, TCR/CD3– Jurkat cells, or primary PBMC 
target cells were incubated with 3CAR or untransduced control effector cells at increasing effector/target 
ratios (E:T ratios) in 96-well microplates for 4 hours at 37°C. 51Cr release was then measured in a micro-
plate scintillation counter (Wallac 1450 MicroBeta TriLux).
Flow-based cytotoxicity assay. CD3-specific CAR T cells or control nontransduced T cells were cocultured 
with TCR/CD3+ Jurkat cells or TCR/CD3– Jurkat target cells that were loaded with CFSE dye (Cell Trace, 
Invitrogen) at the E:T ratio 1:1 (100,000 of  both effector and target cells) for 24 hours. Dot plots show rep-
resentative frequency of  gated CFSE+ tumor cells at the end of  coculture (Figure 3C). CD3 CAR T cells 
or control nontransduced T cells also were cocultured with healthy donor PBMC, CD3+, or CD3– cells 
(MicroBeads, Miltenyi, Bergisch-Gladbach).
Cytokine production. 3CAR-transduced cells were thawed, washed, and resuspended in RPMI 10% FCS 
at a concentration of  1 × 106/ml. TCR/CD3– Jurkat cells, TCR/CD3+ Jurkat cells, and healthy donor 
PBMC were all counted and also adjusted to a concentration of  1 × 106/ml. Cells were mixed at a 1:1 ratio 
in 24-well tissue culture plates and incubated at 37°C. After 24 hours, supernatants were harvested and 
stored at −80°C. Levels of  cytokine in the stored supernatants were quantified using the Th1/Th2/Th17 
cytometric bead array kit (CBA; BD Biosciences) as per the manufacturer’s protocol.
Mixed leukocyte reaction and 3H-thymidine incorporation. To assess allogeneic T cell proliferation in a 
mixed leukocyte reaction (MLR), 3CAR T cells were mixed with target PBMC or PBMC depleted of  CD3 
using CD3 MicroBeads, (Miltenyi, Bergisch-Gladbach), in RPMI 10% FCS at a 1:1 ratio in 96-well plates. 
To asses a 1-way MLR, targets cells were irradiated (30 Gy) prior to coculture. Targets alone were used as 
negative controls, and all cultures were run in triplicate. After coincubation for 5 days, 3H-thymidine (1 
μCi per well) was added for 18 hours before harvesting onto filter mats for radioactivity measurement in a 
scintillation counter (Wallac 1450 MicroBeta TriLux).
In vivo antitumor activity. Ten-week-old female NSG mice (Charles River, strain: NSG [005557] from The 
Jackson Laboratory), were inoculated i.v. with 10 × 106 TCR+ or TCR– Jurkat T cell tumor targets by tail vein 
injection on day 0. The Jurkat T cell targets had been stably transduced to express both EGFP and luciferase 
and, following TALEN-mediated TCRαβ disruption, had been sorted for TCR+ and TCR– expressers. Tumor 
engraftment was confirmed by in vivo imaging of  bioluminescence using an IVIS Lumina III In Vivo Imaging 
System (PerkinElmer, live image version 4.5.18147) on day 3 (19). TCR+- or TCR–-injected mice were further 
injected on day 4 with either PBS (n = 2), 10 × 106 untransduced T cells (n = 4), or 10 × 106 3CAR T cells (n 
= 5) per tumor group. Analysis of  tumor clearance was performed by serial bioluminescent imaging on days 
3, 7, 11, and 18, and processing of  BM for the monitoring of  tumor progression vs. clearance was carried out 
on day 18. BM samples were processed by a RBC lysis, followed by staining for flow cytometry.
Primary T-ALL blasts. Primary T-ALL patient samples are all from the ALL2003 trial, where peripheral 
blood was often sent at diagnosis instead of  bone marrow, with information on CD3+ status and oth-
er surface antigens (Table 1) (a gift from Bloodwise Childhood Leukaemia Cell Bank, Stockport, United 
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Kingdom). To phenotype patient cells, cells were stained with the following primary antibodies: mouse 
anti–human CD3 (clone BW264/56; Miltenyi Biotec), mouse anti–human CD7 (clone M-T701), mouse 
anti–human CD19 (clone SJ25C1), and mouse anti–human CD34 (clone 8G12) (all from BD Biosciences). 
For FACS-Based Killing assay, CD3 CAR T cells, control CAR19 T cells, or control nontransduced T cells 
were cocultured with T-ALL patient sample target cells that were loaded with CFSE dye (Cell Trace, Invit-
rogen), at the E:T ratio 1:1(100,000 of  both effector and target cells) for 24 hours.
Statistics. For in vitro studies, data points from individual donors are shown in all figures. Statistical 
significance in pairwise comparisons was determined by unpaired 2-tailed Student t test. For in vivo stud-
ies, a 2-tailed Man-Whitney U test was used for nonparametric comparison of  grouped data, and values 
are presented as mean percentages of  3 or more samples with SEM or SD, or as a median with the 25th 
and 75th percentiles stated. Linear regression was used for the comparison of  serial measurements, taking 
each y value as an individual point. In all experiments, P < 0.05 was considered statistically significant. All 
statistical analysis was performed using GraphPad Prism software version 5.01.
Study approval. Human sample collections were approved by University College London (UCL) ethics 
committee and collected with written consent. Leukemia samples were provided by the Childhood Leukae-
mia Cell Bank. All animal studies were approved by the UCL Biological Services Ethical Review Committee 
and licensed under the Animals (Scientific Procedures) Act 1986 (Home Office, London, United Kingdom).
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